To cite this paper use one of the standards below:
A series of pyrazoline–dihydropyrimidinone (Pyr–DHPM) hybrid compounds was synthesized in good yields (70–86%) through a multistep synthetic route followed by the copper-catalyzed azide–alkyne cycloaddition (CuAAC) reaction,1 affording a 1,2,3-triazole linker between the two pharmacophores.2 All hybrids were fully characterized by standard spectroscopic techniques. Molecular hybridization is a well-established strategy in medicinal chemistry that enables the development of multitarget-directed agents.3 Considering the urgent need for more selective therapies against colorectal cancer,4 the cytotoxic activity of the Pyr–DHPM hybrids was evaluated in HCT-116, HCT-15, DIFI, and LoVo colorectal cancer cell lines.5 Several compounds reduced cell viability, with the most pronounced and selective effects observed in LoVo cells (29.5–45.9% viability reduction) while exhibiting lower toxicity toward non-malignant HFF-1 cells. These findings identify Pyr–DHPM hybrids as promising scaffolds for further optimization as potential colorectal anticancer agents.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper